Kornimate/medical-research-clean huggingface dataset:
regulation of intestinal and hepatic lipoprotein production by glucagon like peptide 2

Conditions: Dyslipidemia

Summary: 1. to assess whether glucagon like peptide 2 (glp-2) affects lipoprotein production (study a) 2. to assess whether glp-2 affects the release of preformed chylomicrons (study b)

study a: using constant feeding with a nasoduodenal tube and stable isotope infusion, mathematical modelling will be utilised to measure lipoprotein production and clearance. the lipoproteins assessed will be apob-100 from the liver and apob-48 from the intestine. studyb: volunteers will be given a liquid meal with retinyl palmitate (vitamin a) to label chylomicrons made from the meal. 7 hours later they will be given glp-2 or placebo. measurements of plasma and trl(triglyceride rich lipoprotein) triglyceride and trl retinyl palmitate will be carried out to see whether glp-2 increases these parameters.

Eligibility criteria:
inclusion criteria: * inclusion criteria: 1. men and women, aged 18 to 60 years 2. body mass index 20 kg/m2 to 30 kg/m2 3. hemoglobin above 130g/l. 4. normal glucose tolerance in response to a 75g, 2-hr oral glucose tolerance test (ogtt) exclusion criteria: * 1. subject has a history of hepatitis/hepatic disease that has been active within the previous two years. 2. any significant active (over the past 12 months) disease of the gastrointestinal, pulmonary, neurological, renal (cr \> 1.5 mg/dl), genitourinary, hematological systems, or has severe uncontrolled treated or untreated hypertension (sitting diastolic bp \> 100 or systolic \> 180) or proliferative retinopathy 3. history of diabetes or ogtt indicative of diabetes or impaired glucose tolerance. 4. any history of ischemic heart disease or clinically significant, active, cardiovascular history including a history of arrhythmia's or conduction delays on ecg, unstable angina, or decompensated heart failure. 5. abnormal liver or thyroid function tests 6. current addiction to alcohol or substances of abuse as determined by the investigator. 7. mental incapacity, unwillingness or language barrier precluding adequate understanding or cooperation 8. taking any prescription or non-prescription medications at the time of the study 9. having donated blood three months prior to and three months post study procedures 10. a pregnancy test will be performed 1 to 3 days prior to each study in all female research participants. those who test positive for pregnancy will be excluded.

Keywords: lipoproteins, apob, glp-2
vitamin d supplementation for treatment of dyslipidemia

Conditions: Dyslipidemias

Summary: this study will be conducted to assess possible reduction in lipid profile (ldl-triglecerides-cholesterol) among pre-menopausal women in vit d group compared to standard treatment group after 3 months \& 6 month of follow up as prophylaxis step for atherosclerosis.

vitamin d receptor gene mutations have been associated with increased incidence of arterial hypertension. while, hyperlipidemia and lipoprotein oxidation in bone is leading to osteoporosis by inhibiting osteoblastic differentiation it has been reported that vitamin d supplementation has shown pro-atherogenic effects in rats, and its deficiency is associated with the deterioration of atherogenesis these contradictory findings on the progression of atherosclerosis were examined in this study. aim: this study will be conducted to assess possible reduction in lipid profile (ldl-triglycerides-cholesterol) among pre-menopausal women in vitamin d group compared to standard treatment group after 3 months \& 6 month of follow up as prophylaxis step for atherosclerosis. subject and methods: randomized clinical trial with double blinding will be performed on two groups study group and control group. the cases will recruited from outpatient clinic of medicine department in mansoura university hospital. sample size: based on pilot study after start of trial study groups: intervention group: high dose vitamin d3 im treatment group according to vitamin d3 level after laboratory assessment. standard treatment group: balanced diet mix of carbohydrate, lipid, protein and fat diet minerals and vitamins for same period of follow up. inclusion criteria : pre-menopausal females (35-45 years old) * no co morbidity * negative history of contraceptive pills or drug history of cholesterol lowering drugs * absent chronic diseases there is possible recruiting of postmenopausal women according to difficulty in finding pre-menopausal women. methods: study patients will be subjected to: * full history taking,clinical examination, anthropometric measurements. * laboratory investigations: vitamin d3 assessment for all study patients. outcome that will be measured before and after follow up: 1. serum 25 hydroxy vitamin d3 2. c reactive protein 3. serum calcium level 4. complete lipid profile: ldl-hdl-triglycerides -total cholesterol quantitative and qualitative assessment.patient will be fasting for at least 12-14 h then 5 ml venous blood sample will be drawn from each patient into plain tube and left to clot. serum for routine analysis and the other aliquot will be stored at -21°c analysis will be separated by centrifugation into two aliquots; one will be used

Eligibility criteria:
inclusion criteria: * premenopausal females (35-45 years) exclusion criteria: * no co morbodity * no lipid lowering drugs or contraceptive pills

Keywords: high dose vitamin d dyslipidemia premenopausal women
physiological responses in experimentally induced cognitive fatigue in people with multiple sclerosis (ms)

Conditions: Multiple Sclerosis; Fatigue; Stress

Summary: the current study will add to the current knowledge by combining several electrophysiological techniques to examine the relationship between physiological responses and cognitive fatigue and daily activity performance in a stress- and fatigue-inducing protocol. the aims of this study are: 1) to evaluate the feasibility and usability of assessing physiological responses in an experimental set-up and 2) to investigate the association between physiological outcomes, experimentally induced stress and cognitive fatigue in people with multiple sclerosis (ms) and healthy controls.

in an experimental set-up participants (20 people with ms and 20 healthy controls) will perform a high-challenging cognitive protocol to provoke stress and (cognitive) fatigue. physiological responses (heart rate variability, skin conductance, body temperature) and brain activity (eeg) will be measured while resting (resting baseline), while speaking as normal (speaking baseline), during protocol performance and following the protocol (post-protocol). demographic and clinical characteristics, as well as levels of perceived fatigue, stress, pain, daily activity performance, quality of life and anxiety and depression will be assessed using medical records and questionnaires. feasibility and usability will be assessed in participants and researcher(s) by standardized questionnaires.

Eligibility criteria:
inclusion criteria: * diagnosis ms, relapsing remitting (rr) type (ms group) * expanded disability status scale (edss) \<6 (ms group) * dutch speaking * normal or corrected vision * feasible use of computer exclusion criteria: * relapse \< 3 months (ms group) * pregnancy * relevant comorbidity (thyroid disease, diabetes, other neurological disorders, metabolic diseases, neuro-endocrine tumor(s) * severe cognitive disability

Keywords: fatigability cognitive fatigue cognitive fatigability
effect of serotonin and levodopa in ischemic stroke

Conditions: Stroke

Summary: cortical plasticity plays a pivotal role in functional recovery after a stroke. neurotransmitter release, facilitates the creation of new synapses and promotes brain plasticity. in a pilot study, will evaluate the potential benefit of drugs that increase the release of neurotransmitters in patients with first stroke.

methods. evaluate 240 consecutive patients with a first ischemic stroke with nihss 5-20 without aphasia and with a previous independent functional status (mrs \<3). patients will be randomized into four arms: 1) control group, 2) treatment with citalopram 20 mg / day, 3) group levodopa (sinemet plus)100 mg / day, 4) group levodopa (sinemet plus) 100 mg / day + citalopram 20 mg / day. the treatment begins within the first 5 days of stroke and is maintained for 6 months. all patients will be treated according to current guidelines for secondary prevention. we will assess the following variables: demographic, vascular risk factors, etiologic subtypes according to toast criteria, neurologic deficit with the nihss scale, cognitive assessment with minimental scale and functional status with scale modified rankin at discharge, 3, 6 and 12 months, symbol digit modalities test (sdmt), gds-15 geriatric depression scale, logical memory of wms-iv . the cognitive assessment and motor functional status will be evaluated by a neuropsychologist and neurologist blinded to treatment assignment.

Eligibility criteria:
inclusion criteria: * • patients with a first stroke with nihss 5-20 points * patients without aphasia to avoid interference in the assessment of depression and cognitive impairment * patients with independent functional status prior to stroke (mrs \<3) * patients without prior cognitive impairment or depressive syndrome assessed by medical history with the patient and family. * the assigned treatment initiated within the first five days of stroke exclusion criteria: * • patients with prior myocardial or cerebral hemorrhage * patients with tia * patients with aphasia * history of cognitive impairment or prior depressive syndrome * patients with no independent functional status mrs greater than or equal to 3 * underlying disease hopefully less than one year of life. * patient pre-treatment with levodopa, an antidepressant or neuroleptic.
functional sucrase deficiency in short bowel syndrome patients with intestinal failure

Conditions: Short Gut Syndrome

Summary: short gut syndrome with intestinal failure patients may have decreased production of disaccharidases, like sucrase, an enzyme responsible for digesting sugar in foods. this can happen due to loss of bowel length from surgery or from loss of cellular function in the intestines due to use of parenteral nutrition intravenously. therefore, patients with these conditions may not be able to digest sucrose (sugar) fully. patients might experience abdominal distension/pain, vomiting and diarrhea when sugar is taken in orally or through the g-tube, which can limit patients' ability to increase oral or g-tube feeds in short gut syndrome patients with intestinal failure. in patients with short gut syndrome and intestinal failure, the administration of exogenous sucrase (enzyme) may improve sucrose (sugar) digestion and thus the ability to tolerate more oral or g-tube feeds.


Eligibility criteria:
inclusion criteria: * short bowel syndrome, of all ages, with dependence on parental support to provide at least 50% of fluid or caloric needs. * must be on diet containing sucrose. * must be willing and able to sign informed consent * adult and pediatric patients (all ages) exclusion criteria: * current iv antibiotic administration for confirmed bout of bacteremia. * no enteral nutrition * any condition, disease, illness, or circumstance that in the investigator's opinion puts the subject at any undue risk, prevents completion of the study, or interferes with analysis of the study results

Keywords: intestinal failure
the clinical impact of e-prf and h-prf on healing after mandibular third molar surgery

Conditions: Platelet-Rich Fibrin

Summary: this clinical trial aims to compare the effect of platelet concentrates e-prf and h-prf on soft and hard tissue healing in healthy individuals after lower third molar surgery. the main questions it aims to answer are: do e-prf and h-prf reduce complications after third molar surgery? do e-prf and h-prf improve soft tissue healing after third molar surgery? do e-prf and h-prf improve hard tissue healing after third molar surgery? participants will be divided into 2 study groups and one control group. third molar surgery will be performed according to standard protocol. in study groups, dentoalveolar defects will be filled with e-prf and h-prf which are products of centrifugation of the patient's blood without additives. soft tissue and hard tissue healing will be compared between the groups.

a randomized, three parallel arms clinical trial. the primary objective is to assess the clinical impact of e-prf vs h-prf vs control on the soft tissue healing and post-op discomfort and complications after mandibular third molar surgery between the three groups during the healing period of 7 days. the secondary objective is to compare bony healing between the three groups over three months using an orthopantomograph (opg) x-ray. all subjects from the university of sarajevo faculty of dentistry with dental clinical center. subjects that are coming for the removal of impacted mandibular third molars and match the inclusion criteria will be told about the research and offered the opportunity to participate.

Eligibility criteria:
inclusion criteria: * orthodontic indication for impacted mandibular third molar surgery * physical status i according to the guidelines of the american society of anesthesiologists (asa) exclusion criteria: * presence of systemic disease * presence of a condition that affects fibrin clot formation * history of radiation therapy or chemotherapy * allergy to penicillin * oral contraceptive usage * smoking habit * status of pregnancy or lactation * presence of any acute local infection * missing the adjacent second molar or indicated for extraction

Keywords: molar, third prf platelet-rich fibrin
the incidence of intra-operative awareness in china and analysis of relevant factors: a multicentre study

Conditions: Intra-Operative Awareness

Summary: medical literature about awareness during general anesthesia is rare in china, and some small sampled studies in china showed a significantly higher incidence (1.5～6%) of intra-operative awareness compared with western countries. the investigators sponsored this multicenter, large sampled, prospective study to determine the incidence of intra-operative awareness in china, and the preservation effect of bis monitor on the incidence of awareness.

background: the incidence of awareness in patients undergoing general anesthesia has been reported in as many as 0.1～0.2% in western countries. but so far，medical literature about awareness during general anesthesia is still rare in china, and some small sampled studies in china showed a significantly higher incidence (1.5～6%) of intra-operative awareness. we believed that this multicenter, large sampled, prospective study would be very necessary for us to determine the incidence of intra-operative awareness in china, and analysis of the relevant factors would help us to understand why was the incidence of awareness in china much higher than that in western countries. methods: this is a prospective, nonrandomized descriptive cohort study that was conducted at 25 academic medical centers in china. 11,197 patients (age\>12, intubation or lma during anesthesia) form 25 medical centers were enrolled to be interviewed by research stuff for evaluation of awareness at the 1st and 4th day after their general anesthesia. the structured interview questions were:⑴what is the last thing you remembered before you went to sleep? ⑵what is the first thing you remembered when you woke up? ⑶can you remember anything between these two periods? ⑷did you dream during your operation? ⑸what was the worst thing about your operation? an evaluation committee independent from the research stuff was constituted to verify the data from the medical centers. and then the incidence of intra-operative awareness in china was determined. general condition and details of the anesthesia procedure of the patients were also recorded during the anesthesia for a binary logistic regression analysis.

Eligibility criteria:
inclusion criteria: * patients received general anesthesia with tracheal intubation or lma * apparently normal mental status exclusion criteria: * pediatric patients (\<12 yr) * those who could not be interviewed in 24 hours after the operations * those unable to communicate in common spoken chinese

Keywords: incidence awareness general anesthesia relevant factor the incidence of intra-operative awareness in china the relevant factors
tewl biomarker study for diabetic foot ulcer recurrence

Conditions: Diabetes; Diabetic Foot; Diabetic Foot Ulcer; Diabetic Wound; Diabetic

Summary: this is a multicenter study of patients with diabetic foot ulcers (dfu) to develop and validate potential tissue-based biomarkers that predict dfu wound recurrence. trans-epidermal water loss (tewl) will be measured on the closed wound site and a location similar to the wound site (reference site). participants will be enrolled within two weeks after closure of their dfu. complete wound healing will be verified at a second visit two weeks later and this visit will start the 16 week timeline where participants will be followed weekly by phone until the earliest of dfu wound recurrence or 16 weeks. participants who experience a dfu wound recurrence and a subset of participants who do not experience a dfu wound recurrence by week 16 will be asked to attend one final visit.


Eligibility criteria:
inclusion criteria: in order to be eligible to participate in this study, an individual must meet all of the following criteria at visit 1: 1. age \> 18 years. 2. willing and able to comply with protocol instructions. 3. clinically diagnosed dfu is closed. 4. clinically diagnosed with diabetes or meeting the american diabetes association (ada) criteria. 5. provides written informed consent. at visit 2, confirmation of complete wound healing, the following additional inclusion criterion must be met: 6. confirmation that the target dfu that was assessed as healed at visit 1 remains healed two weeks later (at visit 2). exclusion criteria: an individual who meets any of the following criteria will be excluded from participation in this study: 1. dfu wounds closed more than 2 weeks before visit 1, or to be closed by flap or graft coverage 2. closed dfu site whose size or location would not allow five separate tewl measurements 3. prisoners

Keywords: biomarker tewl trans epidermal water loss dfc diabetic foot consortium
nexium capsules s-cei for justification of esomeprazole in acid related disease for reflux symptom healing based on patient clinical outcomes

Conditions: Reflux Esophagitis

Summary: the objective of this investigation is to collect following data in patients given nexium capsule (nexium) in usual post-marketing use.

primary objective to investigate treatment response to nexium in patients with reflux esophagitis (re). secondary objectives to investigate following items in patients with re: 1. patient satisfactory level of the treatment for re 2. health-related quality of life (hrqol) 3. severity and frequency of re symptoms reported by physicians 4. endoscopic healing rate 5. development of adrs

Eligibility criteria:
inclusion criteria: * patients to be enrolled in this s-cei must fulfill all the criteria below at the start of the treatment with nexium. 1. aged at least 20 years. 2. patients who has a current or past history of clinically diagnosed re 3. patients whose answers in the baseline gerdq include "2-3 days" or "4-7 days" in at least one of the questions nos 1, 2, 5 and 6. 4. patients to whom nexium 20 mg once daily is to be administered for re 5. patients from whom written consent has been obtained. exclusion criteria: * patients must not enter the investigation if any of the following exclusion criteria are fulfilled at the start of the treatment with nexium: 1. patients whose ability to follow instructions are suspected to be low by physicians 2. patients with a past history of hypersensitivity to the ingredients of nexium. 3. patients receiving atazanavir sulfate or rilpivirine hydrochloride 4. patients who have received nexium within the past eight weeks for treatment of re

Keywords: reflux esophagitis nexium
live stream of prehospital point-of care ultrasound during cardiopulmonary resuscitation

Conditions: Cardiopulmonary Resuscitation; Echocardiography; Ultrasound

Summary: background: point-of-care ultrasound (pocus) has been suggested as a useful tool in out-of-hospital cardiac arrest (ohca) for diagnosis and treatment of reversible causes. however, in prehospital emergency medicine performing ultrasound and the translation of the findings can be challenging. as new prehospital ultrasound devices offer the possibility for remote supervision, the impact of tele-supervision on the performance of pocus during ohca is unclear. aims: this prospective observational study aims to evaluate if pocus with tele-supervision can be performed during cpr without any additional hands-off periods longer than 5 seconds. methods: in total 30 patients with ohca, where pocus is considered, will be included in this study.


Eligibility criteria:
inclusion criteria: patients with prehospital cardiac arrest, where pocus is considered during cardiac pulmonary resuscitation, will be included. exclusion criteria: * under the age of 18, * if pocus is not considered or if pocus will lead to a delay of live-saving treatment or transportation. * pregnant patients * patients with a body-mass-index (bmi) above 35 kg/m2

Keywords: ultrasound diagnstics prehospital emergency medicine telemedicine
spinal motor evoked potentials in brain surgery

Conditions: Brain Tumor; Glioma

Summary: during neurosurgical resection of brain tumors within brain areas for motor control, it is important to monitor motor function. for this muscle motor evoked potentials are used. those are elicited by transcranial and direct cortical stimulation. motor responses are recorded from muscles. in neurosurgical procedures for spinal cord tumors, the same methods are used, but additionally motor activity is recorded from the spinal cord. this is called spinal motor evoked potentials. it is known that the relation between spinal and muscle motor evoked potentials helps to extent the resection of spinal cord tumors. this study implements the spinal motor evoked potential into brain tumor surgery and analyses the relationship between spinal and muscle motor evoked potentials. with this, detection of injury to the brain area for motor control might be discovered earlier and thus tumor resection can be performed safely.


Eligibility criteria:
inclusion criteria: * \> 18 years * tumor location adjacent to the motor cortex and corticospinal tract exclusion criteria: * minor * neurological degenerative diseases * neurological immunological diseases * drug abuse * implanted medical devices such as cardiac pacemaker * spine deformation

Keywords: muscle motor evoked potentials spinal motor evoked potentials d-wave brain tumor surgery intraoperative neuromonitoring